Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

ESTA US Equity

Establishment Labs Holdings Inc.Health Care · Orthopedic, Prosthetic & Surgical Appliances & Supplies · CIK 1688757 · FY ends Dec 31
$75.22
-1.41 (-1.83%)
USD · as of 2026-08-18 · marketstack
7 registered studies · 4 active

Studies where ESTA is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.

4 interventional · 3 observational

Held by 12 tracked-famous managers (D. E. Shaw & Co., Inc., TWO SIGMA INVESTMENTS, LP, JANE STREET GROUP, LLC, CITADEL ADVISORS LLC, RENAISSANCE TECHNOLOGIES LLC, +7 more) · FINRA short interest 9.9 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 4 sells · government filings 180d: none disclosed

StudyPhaseStatusInterventionsConditionsEnrollmentPrimary completionReadout inUpdated
Clinical Study on Tissue Preservation in Breast Augmentation and ReconstructionNCT07623564observationalNumber of Adverse Events Related to Tissue PreservationEnrolling by invitationProcedure: Mia Harmonization, Mia Scarless Lift, Mia Reconstruction, Joy Dot, Maxtopexia + MiaBreast Augmentation and Breast Reconstruction, Mammaplasty, Breast Augmentation, Tissue Preservation602026-12-31in 134 d2026-06-03
Motiva Flora® Aesthetic Breast Recon® Clinical StudyNCT06146231Total adverse envent rateOpen-label · OtherNot applicableRecruitingDevice: Motiva Flora® Tissue ExpanderMammaplasty, Breast Cancer, Poland Syndrome66Apr 20262025-11-26
Adaptive Study to Assess the Safety and Functioning of Motiva Devices on Minimally Invasive Gluteal AugmentationNCT07135011Primary Safety e:valuationOpen-label · OtherNot applicableRecruitingDevice: Primary gluteal enhancementDevice Safety120Apr 20262025-08-21
Motiva Flora Tissue Expander PMCFNCT05447988Incidence of the device and procedure-related adverse eventsOpen-label · TreatmentNot applicableRecruitingDevice: Breast Tissue ExpanderBreast Tissue Accessory, Breast Cancer1362024-12-152024-08-27
Mia® Clinical StudyNCT06792409SafetyOpen-label · OtherNot applicableCompletedDevice: Minimally invasive breast augmentation procedure with a trans-axillary approach.Breast Augmentation1002024-08-08actual2025-01-24
Retrospective Data Collection on the Use of Motiva Flora TE in Breast ReconstructionNCT05459064observationalSafety - adverse eventsCompletedDevice: Motiva Flora TEBreast Cancer1442024-06-30actual2024-08-27
Safety and Performance of Motiva® SizersNCT06274736observationalMotiva Sizers Safety (complications)CompletedDevice: Motiva SizerBreast Implant; Complications, Breast Implantation; Methods, Safety and Performance, Mammaplasty, Breast Reconstruction, Breast Augmentation1332023-12-10actual2026-06-02

Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.

Source: ClinicalTrials.gov, retrieved 2026-08-19